Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-26-009983
Filing Date
2026-03-13
Accepted
2026-03-13 08:00:03
Documents
1
Period of Report
2026-03-11

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3112
  Complete submission text file 0001493152-26-009983.txt   4576
Mailing Address 804, 322 - 11 AVENUE SW CALGARY Alberta, Canada
Business Address 804, 322 - 11 AVENUE SW CALGARY Alberta, Canada 4036707377
ONCOLYTICS BIOTECH INC (Issuer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O DIAMEDICA THERAPEUTICS INC. 301 CARLSON PARKWAY, SUITE 210 MINNEAPOLIS MN 55305
Business Address
Parsons James T. (Reporting) CIK: 0001759855 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38512 | Film No.: 26750106